Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 17/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3277384 | 0.98 | CD274 (0.45) | CD274SSTR4SSTR1SSTR2SSTR3 | |
| SCHEMBL22513280 | 0.85 | SSTR4 (0.46) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL4343351 | 0.82 | SSTR4 (0.41) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL3279695 | 0.82 | S1PR1 (0.46) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL3281172 | 0.81 | PRCP (0.51) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Hydrochloric Acid SCHEMBL3277256 | 0.81 | S1PR1 (0.39) | CD274SSTR4SSTR1SSTR2SSTR3 | |
| Hydrochloric Acid SCHEMBL3277084 | 0.81 | S1PR1 (0.45) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Hydrochloric Acid SCHEMBL3275740 | 0.81 | SSTR4 (0.42) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Hydrochloric Acid SCHEMBL3276983 | 0.80 | S1PR1 (0.39) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Hydrochloric Acid SCHEMBL3283446 | 0.80 | S1PR1 (0.43) | CD274SSTR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | CD274 3881/4885SSTR4 468/4885SSTR1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.